Aimee Usera, Ph.D.

Dr. Aimee Usera brings to Delphia broad experience in medicinal chemistry and drug discovery spanning disease areas and therapeutic modalities, with a focus in oncology.  With multiple patents, publications and a strong track record of leading highly functional multidisciplinary and culturally outstanding teams, Aimee oversees chemistry at Delphia.

Prior to joining Delphia, Aimee also served in a leadership role as vice president of chemistry at Odyssey Therapeutics. Aimee’s previous industry experience includes leadership across several projects and portfolios within global discovery chemistry at Novartis Biomedical Research. During her time at Novartis, Aimee was a pioneer chemist in the new modalities group, bringing the group’s first compound to the clinic. Over more than a decade, she discovered novel chemical entities and established new technologies to advance programs through preclinical development. 

In addition to her work in the oncology and cardiovascular disease areas, Aimee also led the global Targeted Protein Degradation Initiative, driving a portfolio of projects across disease areas from target discovery to the clinic. 

Aimee holds a B.A. in chemistry from College of the Holy Cross and a Ph.D. in chemistry from Johns Hopkins University. After her time in Baltimore, Maryland, Aimee continued her studies as an NIH postdoctoral fellow at MIT, where she studied terpene indole alkaloid biosynthesis toward the discovery of alkaloid-based cancer therapeutics.